CAMBRIDGE, Mass. (AP) _ Seres Therapeutics Inc. (MCRB) on Wednesday reported a loss of $27.9 million in its first quarter.
The Cambridge, Massachusetts-based company said it had a loss of 69 cents per share.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 75 cents per share.
The drug developer posted revenue of $4 million in the period.
Seres Therapeutics shares have declined 18 percent since the beginning of the year. The stock has dropped 14 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MCRB at https://www.zacks.com/ap/MCRB